Bedrocan on Hold Amid Uncertainty Over Medical Cannabis

Bedrocan, one of the best-known names in the European medical cannabis industry, has been granted a suspension of payments in the Netherlands as financial pressure on the company mounts. This proceeding involves Bedrocan Nederland and Bedrocan International, while its subsidiaries in Denmark and Canada are not affected.

The Dutch producer, which has been supplying standardized medical cannabis on behalf of the government since 2003, finds itself caught between the end of a government contract and delays in regulatory reforms that were supposed to open up new business opportunities for it.

The suspension of payments gives Bedrocan a temporary reprieve while it explores possible solutions with management, creditors, and customers. Although such proceedings may lead to bankruptcy, the company still hopes to find a way forward.

Spokesperson Femke Starrenburg described the situation as a «ray of hope.».

From Government Contractor to Regulatory Uncertainty

For more than two decades, Bedrocan stood out from the rest in the Dutch medical cannabis system. Its products were supplied through the’Office of Medical Cannabis (BMC), which oversees the production, sale, and export of medical cannabis in the Netherlands.

The Dutch government has sought to reform this model and give producers more flexibility to market their products directly. However, such a change requires an amendment to the Opium Act, in particular to authorize direct sales to pharmacies in the Netherlands and abroad.

According to Bedrocan, the reform is taking much longer than expected, and a decision is now not expected until 2028 at the earliest.

«The delay in passing this legislative amendment has put us in a very difficult situation. And we are now facing problems.»

At the same time, the contract for Bedrocan's agreement with the government expired in January. According to Mr. Starrenburg, this dual situation has left the company with insufficient domestic orders to cover its costs. Cannabis cultivation, which is particularly energy-intensive, results in high electricity costs that weigh heavily on the company’s finances.

International Exports at the Heart of Bedrocan's Challenges

The loss of exports from the Netherlands appears to be having particularly severe consequences. Bedrocan previously exported large volumes of medical marijuana through BMC, as international markets account for a significant portion of its business.

The company had anticipated changes to the Dutch system and had expanded abroad, by establishing a presence in Denmark and in Canada. Its Danish facility can export to European markets, particularly Germany and Italy, but its capacity remains limited.

«But this is a small facility, and we can’t supply Europe or the whole world from here. We simply need the Netherlands for that.»

The suspension currently affects Bedrocan's Dutch production sites in Zuidwending and Emmeloord, as well as its offices in Veendam and Amsterdam. In total, these operations account for just under 70 full-time equivalent jobs.

The supply of medical cannabis is causing concern among patients

Beyond Bedrocan's financial situation, the situation raises questions about the continuity of the’Dutch supply of medical cannabis. According to the company, approximately 7,000 patients currently use medical cannabis prescribed by a doctor, including people with epilepsy, chronic pain, and multiple sclerosis.

Bedrocan has agreed with the Dutch Ministry of Health, Welfare, and Sports to build up stockpiles. However, the company notes that its current products have a shelf life of about one year, which could create difficulties if Dutch production were to cease before a new regulatory framework is put in place.

Patient advocacy groups and the trade association Hollandbio have raised the issue with Dutch lawmakers, while members of several political parties have questioned the government about future supply.

One of the options being considered is to import medical cannabis to offset a potential decline in domestic production, an approach that has been strongly criticized by Bedrocan.

«When we read that in the minister’s letter to the House of Representatives, we were truly stunned. We have in the Netherlands from an experienced producer, », which has all the necessary facilities and is capable of solving this problem, and yet they want to source their supplies from abroad. We find this inexplicable."

For now, the suspension of payments gives Bedrocan time to assess whether its Dutch operations can be maintained. In any case, the producer’s situation already illustrates the challenges associated with the transition from a strictly regulated public supply model to a more open medical cannabis market, for which the regulatory framework has yet to take shape.